

---

## Program

Thursday, June 14, 2012

- 8:15 Registration  
8:45 President *Welcome*  
8:50 Enrico Mihich *Introduction*  
9:00 David Livingston *Focus & Goals*  
8:45 Jeffrey Engelman – *Keynote Address: Challenges in overcoming resistance to kinase inhibitors*

### Session I, Genetics of Resistance I

Chair/Moderator: Lewis Chodosh

- 10:00 Lewis Chodosh – *Mechanisms of tumor dormancy and recurrence*  
10:25 Discussion  
10:45 Coffee break  
11:05 Elaine Mardis – *Genomic exploration of therapy resistance*  
11:30 Discussion  
11:50 Thomas O'Hare – *Compounding the problem of clinical resistance to TKIs in CML*  
12:15 Discussion  
12:35 Levi Garraway – *Defining the spectrum of resistance to targeted anti-cancer agents*  
13:00 Discussion  
13:20 Lunch

### Session II, Clinical Advances in Overcoming Resistance

Chair/Moderator: Jose Baselga

- 14:30 Jose Baselga – *Reverting endocrine resistance by targeting the mTOR pathway: A new paradigm in the therapy of breast cancer*  
14:55 Discussion  
15:15 Jeff Sosman – *Clinical approaches to BRAF inhibitor resistance in melanoma*  
15:40 Discussion  
16:00 Johan deBono – *Improving outcome from prostate cancer*  
16:25 Discussion  
16:45 Adjourn

3

The Pezcoller Symposia

---

## Program

Friday, June 15, 2012

### Session III, Resistance through Perturbed Signaling

Chair/Moderator: Richard Marais

- 8:30 Richard Marais – *BRAF and RAS signaling in cancer; translating basic understanding into clinical benefit*  
8:55 Discussion  
9:15 Alberto Bardelli – *Mechanisms of resistance to EGFR targeted therapies in colorectal cancer*  
9:40 Discussion  
10:00 Coffee break  
10:20 Neal Rosen – *Adaptive resistance to oncoprotein inhibition*  
10:45 Discussion  
11:05 Rafaella Sordella – *Intrinsic and extrinsic mechanisms of erlotinib resistance in NSCLC*  
11:30 Discussion  
11:50 Poster Session & Lunch

### Session IV, Genetics of Resistance II

Chair/Moderator: William Sellers

- 14:00 William Sellers – *Approaches to the discovery and treatment of therapeutic resistance*  
14:25 Discussion  
14:45 Jos Jonkers – *Studying therapy response and resistance in mouse models BRCA-associated breast cancer*  
15:10 Discussion  
15:30 Roman Thomas – *Lung cancer genomics*  
15:55 Discussion  
16:25 Giulio Superti-Furga – *Effectors and targets of anti-cancer agents*  
16:50 Discussion  
17:10 Silvia Buonamici – *Identifying the mechanisms of resistance to smoothed inhibitors*  
17:35 Discussion  
17:50 Adjourn  
20:00 Symposium Dinner

4

The Pezcoller Symposia

---

## Program

Saturday, June 16, 2012

- 8:00 Best Posters' Oral Presentations

### Session V, Role of the Tumor Microenvironment in Resistance

Chair/Moderator: David Tuveson

- 9:00 David Tuveson – *The pancreatic tumor stroma influences therapeutic response*  
9:25 Discussion  
9:45 Ben Stanger – *The dynamics of primary tumor spread in pancreatic cancer*  
10:10 Discussion  
10:30 James Allison – *Immune checkpoint blockade: New insights and opportunities*  
10:50 Discussion  
11:20 Todd Golub – *Systematic approaches to discovering microenvironment-mediated drug resistance*  
11:45 Discussion  
12:05 David Livingston – *Concluding Remarks*  
12:30 Lunch & Adjourn

5

The Pezcoller Symposia

---

## Invited Participants

- **James Allison**  
Memorial Sloan Kettering Cancer Ctr, New York, NY
- **Alberto Bardelli**  
Inst for Cancer Res & Treatment, Candiolo, Torino, Italy
- **Jose Baselga**  
Massachusetts General Hospital, Boston, MA  
Vall D'Hebron Inst of Oncology, Barcelona, Spain
- **Silvia Buonamici**  
Novartis Inst for Biomedical Res, Cambridge, MA
- **Lewis Chodosh**  
Univ of Pennsylvania, Philadelphia, PA
- **Johann De Bono**  
Institute of Cancer Research, London, UK
- **Jeffrey Engelman**  
Massachusetts General Hospital, Charlestown, MA
- **Levi Garraway**  
Dana Farber Cancer Inst, Boston, MA
- **Todd Golub**  
Broad Inst at MIT, Cambridge, MA
- **Jos Jonkers**  
Netherlands Cancer Inst, Amsterdam, NL
- **David Livingston**  
Dana Farber Cancer Inst, Boston, MA
- **Richard Marais**  
The Inst of Cancer Research, London, UK

6

The Pezcoller Symposia

---

## Invited Participants

- **Elaine Mardis**  
The Genome Inst at Washington Univ, St. Louis, MO
- **Enrico Mihich**  
Dana Farber Cancer Inst, Boston, MA
- **Thomas O'Hare**  
Univ of Utah School of Medicine, Salt Lake City, UT
- **Neal Rosen**  
Memorial Sloan Kettering Cancer Ctr, New York, NY
- **William Sellers**  
Novartis Inst for Biomedical Res, Cambridge, MA
- **Rafaella Sordella**  
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
- **Jeffrey Sosman**  
Vanderbilt Univ, Nashville, TN
- **Ben Stanger**  
University of Pennsylvania, Philadelphia, PA
- **Giulio Superti-Furga**  
CeMM Res Ctr Molecular Medicine, Vienna, Austria
- **Roman Thomas**  
University Hospital Cologne, Cologne, Germany
- **David Tuveson**  
Cambridge Research Inst, Cambridge, UK

---

## The Pezcoller Foundation

The Pezcoller Foundation is a non-profit organisation created in 1980 by Prof. Alessio Pezcoller (1896 - 1993), Chief Surgeon of Santa Chiara Hospital of Trento, Italy. The goal of the Foundation is to promote biomedical research.

Activities:

- **PEZCOLLER FOUNDATION-AACR INTERNATIONAL AWARD FOR CANCER RESEARCH** – 75.000 Euro: this prize is presented, every year, to a scientist who has made a major scientific discovery in the field of cancer.
- **PEZCOLLER FOUNDATION-ECCO RECOGNITION FOR CONTRIBUTION TO ONCOLOGY** – 30.000 Euro: this prize is presented, every two years to a single individual (scientist, clinician, nurse. etc.) for his/her professional life dedication to the improvement of cancer treatment, care and research.
- **THE PEZCOLLER SYMPOSIA**: a series of annual symposia promoting interactions among scientists working at the cutting edge of basic oncological sciences.
- **PEZCOLLER SEMINARS**: a series of educational meetings for medical doctors.
- **PEZCOLLER FOUNDATION FELLOWSHIPS**: for professional updating in oncology.
- **PEZCOLLER FOUNDATION GRANTS**: for oncological research programs.
- **THE PEZCOLLER FOUNDATION JOURNAL**: this periodical is published in order to provide a direct link, at six month interval, between the Pezcoller Foundation and the international medical and scientific community.

## This Symposium is supported by

- Fondazione Cassa di Risparmio di Trento e Rovereto
- Provincia Autonoma di Trento
- Comune di Trento
- Comune di Rovereto

---

8

The Pezcoller Symposia

## 24<sup>th</sup> Pezcoller Symposium

# MOLECULAR BASIS FOR RESISTANCE TO TARGETED AGENTS

Trento, Italy,  
June 14-16, 2012



Fondazione PEZCOLLER  
Via Dordi, 8  
38122 TRENTO - Italy  
Tel. 0039 - 0461 - 980250  
Fax 0039 - 0461 - 980350  
E-mail: [pezcoller@pezcoller.it](mailto:pezcoller@pezcoller.it)  
Web: [www.pezcoller.it](http://www.pezcoller.it)

---

## The Pezcoller Foundation Symposia

### 24<sup>th</sup> Pezcoller Symposium **MOLECULAR BASIS FOR RESISTANCE TO TARGETED AGENTS**

Trento, Italy, June 14-16, 2012  
Conference Hall of Fondazione Cassa di Risparmio di Trento e Rovereto, via Calepina 1 – 38122 Trento

*Co-Chairmen and Program Committee*  
Richard Marais, William Sellers,  
David Livingston and Enrico Mihich

---

The topic will be *Molecular Basis for Resistance to Target Agents* and the focus of the meeting will be the mechanisms of resistance to new tumour target therapies. The Symposium will be opened by the keynote address of Prof. J. Engelman, MGH. The meeting is being co-organized by William Seller (UK), Richard Marais (UK), David Livingston (Dana Farber Cancer Institute) and with the collaboration of Enrico Mihich (Dana Farber Cancer Institute) There will be 22 speakers divided in five sessions: A) the genetics of this phenotype ; B) cooption of specific signal transduction events resulting in drug resistance ; C) advanced approaches to screening for various forms of resistance ; D) non-tumor cell directed resistance processes ; E) clinical advances in overcoming resistance. Speakers give approximately 25 minute talks followed by a similar amount of time for audience discussion. These meetings have regularly provided a fertile climate for highly revealing and stimulating scientific discussion on topics of extraordinary interest in cancer science.

---

2

The Pezcoller Symposia

---

7

The Pezcoller Symposia